GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » ROIC %

Hua Medicine (HKSE:02552) ROIC % : -87.03% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Hua Medicine's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2024 was -87.03%.

As of today (2025-04-06), Hua Medicine's WACC % is 13.43%. Hua Medicine's ROIC % is -102.54% (calculated using TTM income statement data). Hua Medicine earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Hua Medicine ROIC % Historical Data

The historical data trend for Hua Medicine's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine ROIC % Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROIC %
Get a 7-Day Free Trial Premium Member Only -209.42 -152.64 -59.95 -67.41 -100.13

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.37 -54.87 -102.87 -122.79 -87.03

Competitive Comparison of Hua Medicine's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hua Medicine's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's ROIC % distribution charts can be found below:

* The bar in red indicates where Hua Medicine's ROIC % falls into.


;
;

Hua Medicine ROIC % Calculation

Hua Medicine's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROIC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=-376.508 * ( 1 - 0% )/( (320.319 + 431.738)/ 2 )
=-376.508/376.0285
=-100.13 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1887.177 - 122.585 - ( 1597.818 - max(0, 275.669 - 1719.942+1597.818))
=320.319

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1630.647 - 124.591 - ( 1216.882 - max(0, 352.621 - 1426.939+1216.882))
=431.738

Hua Medicine's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2024 is calculated as:

ROIC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-342.122 * ( 1 - 0% )/( (354.503 + 431.738)/ 2 )
=-342.122/393.1205
=-87.03 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1781.448 - 129.594 - ( 1441.286 - max(0, 334.887 - 1632.238+1441.286))
=354.503

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1630.647 - 124.591 - ( 1216.882 - max(0, 352.621 - 1426.939+1216.882))
=431.738

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hua Medicine  (HKSE:02552) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Hua Medicine's WACC % is 13.43%. Hua Medicine's ROIC % is -102.54% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Hua Medicine ROIC % Related Terms

Thank you for viewing the detailed overview of Hua Medicine's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hua Medicine Business Description

Traded in Other Exchanges
N/A
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Executives
Chen Li 2101 Beneficial owner
Hlyy Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
Hong Jane Xingfang 2202 Interest of your spouse
Wuxi Pharmatech Investments (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd. 2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited 2201 Interest of corporation controlled by you
Nelsen Robert Taylor 2101 Beneficial owner
Venrock Management V, Llc 2102 Investment manager
Harvest Yuanxiang (cayman) Limited 2101 Beneficial owner
Arch Venture Fund Vii, L.p. 2101 Beneficial owner

Hua Medicine Headlines

No Headlines